NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD
5.01
-0.24 (-4.57%)
The current stock price of UNCY is 5.01 USD. In the past month the price decreased by -20.48%. In the past year, price increased by 1.23%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.74 | 339.94B | ||
AMGN | AMGEN INC | 14.22 | 158.77B | ||
GILD | GILEAD SCIENCES INC | 14.17 | 136.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.40B | ||
REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.30B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.07B | ||
ARGX | ARGENX SE - ADR | 97.43 | 34.21B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.14B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.39 | 27.09B | ||
NTRA | NATERA INC | N/A | 21.91B | ||
BIIB | BIOGEN INC | 8.48 | 19.67B | ||
INSM | INSMED INC | N/A | 18.63B |
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 22 full-time employees. The company went IPO on 2021-06-17. The firm's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 14
Phone: 16503840642
The current stock price of UNCY is 5.01 USD. The price decreased by -4.57% in the last trading session.
The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.
UNCY stock is listed on the Nasdaq exchange.
UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 63.98M USD. This makes UNCY a Micro Cap stock.
UNICYCIVE THERAPEUTICS INC (UNCY) currently has 14 employees.
UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 4.63 and a resistance level at 5.39. Check the full technical report for a detailed analysis of UNCY support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UNCY does not pay a dividend.
UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.1).
ChartMill assigns a fundamental rating of 2 / 10 to UNCY. While UNCY seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -5.1. The EPS increased by 59.2% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -119.44% | ||
ROE | -509% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to UNCY. The Buy consensus is the average rating of analysts ratings from 13 analysts.